跳至主要内容
临床试验/EUCTR2005-005793-75-DK
EUCTR2005-005793-75-DK进行中(未招募)不适用

Evaluation of the efficacy of a topical formulation containing ASF-1075 in the treatment of chronic hand dermatitis - hand dermatitis

Astion Danmark A/S0 个研究点目标入组 40 人开始时间: 2006年1月30日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • men and women aged 18 to 70 years;
  • patients suffering from chronic hand dermatitis rated mild to moderate according to Investigator’s global assessment and which has persisted for more than 6 month in spite of attempts to identify and remove cause;
  • the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;
  • sexually active females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intrauterine device (IUD), condom with intravaginal spermicide;
  • written informed consent obtained.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • patients with primary hyperkeratotic forms of dermatitis, hand dermatosis other than eczematous dermatoses or with acute infection;
  • patients with allergic contact dermatitis if the allergen is identified and they remained in contact with the allergen;
  • metalworker;
  • Suntan, hyperpigmentation or tattoos in the test fields;
  • dark-skinned persons whose skin color prevents ready assessment of skin reactions;
  • treatment within 3 months before study day 1 with systemic medications (i.e. glucocorticoids or immune modulators), treatment within two weeks with topical glucocorticosteroids, or treatment with other systemic or locally acting medications which might counter or influence the trial aim within two weeks before study day 1 and during the study;
  • UV-therapy within 4 weeks before study day 1 and during the study;
  • patients with skin cancer in the medical history;
  • patients known to be drug-resistant for this indication;
  • evidence of drug or alcohol abuse;
  • pregnancy or nursing;
  • symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before study day 1 and during the study;
  • participation in another clinical trial involving pharmaceutical products in the four weeks before study day 1;
  • known allergic reactions to components of the study preparations;
  • in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e.g. due to probable noncompliance or inability to understand the study and give adequately informed consent.

研究者

发起方
Astion Danmark A/S

相似试验

Evaluation of the efficacy of a topical formulation... | 临床试验